Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q96NU7
UPID:
HUTI_HUMAN
Alternative names:
Amidohydrolase domain-containing protein 1
Alternative UPACC:
Q96NU7; A8K463; Q68CI8
Background:
Probable imidazolonepropionase, also known as Amidohydrolase domain-containing protein 1, plays a crucial role in the metabolism of certain amino acids. This enzyme is pivotal in the catalytic conversion processes, facilitating the breakdown of complex molecules into simpler forms that are essential for various bodily functions.
Therapeutic significance:
Understanding the role of Probable imidazolonepropionase could open doors to potential therapeutic strategies. Its involvement in amino acid metabolism suggests its potential impact on metabolic disorders, offering a promising avenue for research and development in drug discovery.